<!DOCTYPE html>
<!--
==============================================================================
           "GitHub HTML5 Pandoc Template" v2.1 — by Tristano Ajmone           
==============================================================================
Copyright © Tristano Ajmone, 2017, MIT License (MIT). Project's home:

- https://github.com/tajmone/pandoc-goodies

The CSS in this template reuses source code taken from the following projects:

- GitHub Markdown CSS: Copyright © Sindre Sorhus, MIT License (MIT):
  https://github.com/sindresorhus/github-markdown-css

- Primer CSS: Copyright © 2016-2017 GitHub Inc., MIT License (MIT):
  http://primercss.io/

~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
The MIT License 

Copyright (c) Tristano Ajmone, 2017 (github.com/tajmone/pandoc-goodies)
Copyright (c) Sindre Sorhus <sindresorhus@gmail.com> (sindresorhus.com)
Copyright (c) 2017 GitHub Inc.

"GitHub Pandoc HTML5 Template" is Copyright (c) Tristano Ajmone, 2017, released
under the MIT License (MIT); it contains readaptations of substantial portions
of the following third party softwares:

(1) "GitHub Markdown CSS", Copyright (c) Sindre Sorhus, MIT License (MIT).
(2) "Primer CSS", Copyright (c) 2016 GitHub Inc., MIT License (MIT).

Permission is hereby granted, free of charge, to any person obtaining a copy
of this software and associated documentation files (the "Software"), to deal
in the Software without restriction, including without limitation the rights
to use, copy, modify, merge, publish, distribute, sublicense, and/or sell
copies of the Software, and to permit persons to whom the Software is
furnished to do so, subject to the following conditions:

The above copyright notice and this permission notice shall be included in all
copies or substantial portions of the Software.

THE SOFTWARE IS PROVIDED "AS IS", WITHOUT WARRANTY OF ANY KIND, EXPRESS OR
IMPLIED, INCLUDING BUT NOT LIMITED TO THE WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT. IN NO EVENT SHALL THE
AUTHORS OR COPYRIGHT HOLDERS BE LIABLE FOR ANY CLAIM, DAMAGES OR OTHER
LIABILITY, WHETHER IN AN ACTION OF CONTRACT, TORT OR OTHERWISE, ARISING FROM,
OUT OF OR IN CONNECTION WITH THE SOFTWARE OR THE USE OR OTHER DEALINGS IN THE
SOFTWARE.
==============================================================================-->
<html>
<head>
  <meta charset="utf-8" />
  <meta name="generator" content="pandoc" />
  <meta name="viewport" content="width=device-width, initial-scale=1.0, user-scalable=yes" />
  <title>Acute kidney injury MeG-CLS-071</title>
  <style type="text/css">
@charset "UTF-8";.markdown-body{-ms-text-size-adjust:100%;-webkit-text-size-adjust:100%;color:#24292e;font-family:-apple-system,system-ui,BlinkMacSystemFont,"Segoe UI",Helvetica,Arial,sans-serif,"Apple Color Emoji","Segoe UI Emoji","Segoe UI Symbol";font-size:16px;line-height:1.5;word-wrap:break-word;box-sizing:border-box;min-width:200px;max-width:980px;margin:0 auto;padding:45px}.markdown-body a{color:#0366d6;background-color:transparent;text-decoration:none;-webkit-text-decoration-skip:objects}.markdown-body a:active,.markdown-body a:hover{outline-width:0}.markdown-body a:hover{text-decoration:underline}.markdown-body a:not([href]){color:inherit;text-decoration:none}.markdown-body strong{font-weight:600}.markdown-body h1,.markdown-body h2,.markdown-body h3,.markdown-body h4,.markdown-body h5,.markdown-body h6{margin-top:24px;margin-bottom:16px;font-weight:600;line-height:1.25}.markdown-body h1{font-size:2em;margin:.67em 0;padding-bottom:.3em;border-bottom:1px solid #eaecef}.markdown-body h2{padding-bottom:.3em;font-size:1.5em;border-bottom:1px solid #eaecef}.markdown-body h3{font-size:1.25em}.markdown-body h4{font-size:1em}.markdown-body h5{font-size:.875em}.markdown-body h6{font-size:.85em;color:#6a737d}.markdown-body img{border-style:none}.markdown-body svg:not(:root){overflow:hidden}.markdown-body hr{box-sizing:content-box;height:.25em;margin:24px 0;padding:0;overflow:hidden;background-color:#e1e4e8;border:0}.markdown-body hr::before{display:table;content:""}.markdown-body hr::after{display:table;clear:both;content:""}.markdown-body input{margin:0;overflow:visible;font:inherit;font-family:inherit;font-size:inherit;line-height:inherit}.markdown-body [type=checkbox]{box-sizing:border-box;padding:0}.markdown-body *{box-sizing:border-box}.markdown-body blockquote{margin:0}.markdown-body ol,.markdown-body ul{padding-left:2em}.markdown-body ol ol,.markdown-body ul ol{list-style-type:lower-roman}.markdown-body ol ol,.markdown-body ol ul,.markdown-body ul ol,.markdown-body ul ul{margin-top:0;margin-bottom:0}.markdown-body ol ol ol,.markdown-body ol ul ol,.markdown-body ul ol ol,.markdown-body ul ul ol{list-style-type:lower-alpha}.markdown-body li>p{margin-top:16px}.markdown-body li+li{margin-top:.25em}.markdown-body dd{margin-left:0}.markdown-body dl{padding:0}.markdown-body dl dt{padding:0;margin-top:16px;font-size:1em;font-style:italic;font-weight:600}.markdown-body dl dd{padding:0 16px;margin-bottom:16px}.markdown-body code{font-family:SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace}.markdown-body pre{font:12px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;word-wrap:normal}.markdown-body blockquote,.markdown-body dl,.markdown-body ol,.markdown-body p,.markdown-body pre,.markdown-body table,.markdown-body ul{margin-top:0;margin-bottom:16px}.markdown-body blockquote{padding:0 1em;color:#6a737d;border-left:.25em solid #dfe2e5}.markdown-body blockquote>:first-child{margin-top:0}.markdown-body blockquote>:last-child{margin-bottom:0}.markdown-body table{display:block;width:100%;overflow:auto;border-spacing:0;border-collapse:collapse}.markdown-body table th{font-weight:600}.markdown-body table td,.markdown-body table th{padding:6px 13px;border:1px solid #dfe2e5}.markdown-body table tr{background-color:#fff;border-top:1px solid #c6cbd1}.markdown-body table tr:nth-child(2n){background-color:#f6f8fa}.markdown-body img{max-width:100%;box-sizing:content-box;background-color:#fff}.markdown-body code{padding:.2em 0;margin:0;font-size:85%;background-color:rgba(27,31,35,.05);border-radius:3px}.markdown-body code::after,.markdown-body code::before{letter-spacing:-.2em;content:" "}.markdown-body pre>code{padding:0;margin:0;font-size:100%;word-break:normal;white-space:pre;background:0 0;border:0}.markdown-body .highlight{margin-bottom:16px}.markdown-body .highlight pre{margin-bottom:0;word-break:normal}.markdown-body .highlight pre,.markdown-body pre{padding:16px;overflow:auto;font-size:85%;line-height:1.45;background-color:#f6f8fa;border-radius:3px}.markdown-body pre code{display:inline;max-width:auto;padding:0;margin:0;overflow:visible;line-height:inherit;word-wrap:normal;background-color:transparent;border:0}.markdown-body pre code::after,.markdown-body pre code::before{content:normal}.markdown-body .full-commit .btn-outline:not(:disabled):hover{color:#005cc5;border-color:#005cc5}.markdown-body kbd{box-shadow:inset 0 -1px 0 #959da5;display:inline-block;padding:3px 5px;font:11px/10px SFMono-Regular,Consolas,"Liberation Mono",Menlo,Courier,monospace;color:#444d56;vertical-align:middle;background-color:#fcfcfc;border:1px solid #c6cbd1;border-bottom-color:#959da5;border-radius:3px;box-shadow:inset 0 -1px 0 #959da5}.markdown-body :checked+.radio-label{position:relative;z-index:1;border-color:#0366d6}.markdown-body .task-list-item{list-style-type:none}.markdown-body .task-list-item+.task-list-item{margin-top:3px}.markdown-body .task-list-item input{margin:0 .2em .25em -1.6em;vertical-align:middle}.markdown-body::before{display:table;content:""}.markdown-body::after{display:table;clear:both;content:""}.markdown-body>:first-child{margin-top:0!important}.markdown-body>:last-child{margin-bottom:0!important}.Alert,.Error,.Note,.Success,.Warning{padding:11px;margin-bottom:24px;border-style:solid;border-width:1px;border-radius:4px}.Alert p,.Error p,.Note p,.Success p,.Warning p{margin-top:0}.Alert p:last-child,.Error p:last-child,.Note p:last-child,.Success p:last-child,.Warning p:last-child{margin-bottom:0}.Alert{color:#246;background-color:#e2eef9;border-color:#bac6d3}.Warning{color:#4c4a42;background-color:#fff9ea;border-color:#dfd8c2}.Error{color:#911;background-color:#fcdede;border-color:#d2b2b2}.Success{color:#22662c;background-color:#e2f9e5;border-color:#bad3be}.Note{color:#2f363d;background-color:#f6f8fa;border-color:#d5d8da}.Alert h1,.Alert h2,.Alert h3,.Alert h4,.Alert h5,.Alert h6{color:#246;margin-bottom:0}.Warning h1,.Warning h2,.Warning h3,.Warning h4,.Warning h5,.Warning h6{color:#4c4a42;margin-bottom:0}.Error h1,.Error h2,.Error h3,.Error h4,.Error h5,.Error h6{color:#911;margin-bottom:0}.Success h1,.Success h2,.Success h3,.Success h4,.Success h5,.Success h6{color:#22662c;margin-bottom:0}.Note h1,.Note h2,.Note h3,.Note h4,.Note h5,.Note h6{color:#2f363d;margin-bottom:0}.Alert h1:first-child,.Alert h2:first-child,.Alert h3:first-child,.Alert h4:first-child,.Alert h5:first-child,.Alert h6:first-child,.Error h1:first-child,.Error h2:first-child,.Error h3:first-child,.Error h4:first-child,.Error h5:first-child,.Error h6:first-child,.Note h1:first-child,.Note h2:first-child,.Note h3:first-child,.Note h4:first-child,.Note h5:first-child,.Note h6:first-child,.Success h1:first-child,.Success h2:first-child,.Success h3:first-child,.Success h4:first-child,.Success h5:first-child,.Success h6:first-child,.Warning h1:first-child,.Warning h2:first-child,.Warning h3:first-child,.Warning h4:first-child,.Warning h5:first-child,.Warning h6:first-child{margin-top:0}h1.title,p.subtitle{text-align:center}h1.title.followed-by-subtitle{margin-bottom:0}p.subtitle{font-size:1.5em;font-weight:600;line-height:1.25;margin-top:0;margin-bottom:16px;padding-bottom:.3em}div.line-block{white-space:pre-line}
  </style>
  <style type="text/css">code{white-space: pre;}</style>
  <!--[if lt IE 9]>
    <script src="//cdnjs.cloudflare.com/ajax/libs/html5shiv/3.7.3/html5shiv-printshiv.min.js"></script>
  <![endif]-->
</head>
<body>
<article class="markdown-body">
<h1 id="acute-kidney-injury">Acute Kidney Injury </h1>
<h2 id="executive-summary"><em>Executive summary</em></h2>
<h2 id="introduction">Introduction</h2>
<p>Acute kidney injury (AKI) is an abrupt decline in renal function usually taking place over hours to days. It is defined by a reduction in urine output and / or a laboratory diagnosis of a decline in renal function i.e. increased serum creatinine (Cr) or reduced glomerular filtration rate (GFR). Acute kidney is a significant risk factor for morbidity and mortality – a moderate elevation of serum creatinine is an independent risk factor for mortality. The causes of AKI in adults are not significantly different from the causes in children, however, different criteria are used to determine the severity of AKI in each age group. AKI may progress to chronic kidney disease(CKD) and may occur in the presence of CKD. It is important to distinguish between the two conditions as interventions and prognosis are very different. The difference is usually temporal.</p>
<h3 id="target-user">Target User</h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Doctors</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Nurses</p>
</div></li>
</ul>
<h3 id="target-area-of-use">Target area of use </h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Ward</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Outpatient department</p>
</div></li>
</ul>
<h3 id="key-areas-of-focus">Key areas of focus </h3>
<p>The main focus of this guideline is to stimulate doctors to recognize and manage AKI promptly. It is necessary to follow up the patients with AKI and those at risk of AKI to reduce morbidity. Furosemide use in the management of AKI is restricted to patients with signs of fluid overload.</p>
<h3 id="limitations">Limitations </h3>
<h2 id="management-of-stage-3-aki-an-indication-for-renal-replacement-therapy-is-not-available-at-csd.-these-patients-must-be-referred-to-efsth.-patients-at-keneba-who-are-suspected-to-have-aki-should-be-referred-for-adequate-management.">Management of stage 3 AKI (an indication for renal replacement therapy) is not available at CSD. These patients must be referred to EFSTH. Patients at Keneba who are suspected to have AKI should be referred for adequate management.</h2>
<h2 id="common-causes">Common causes: </h2>
<p>The following are common causes of AKI in this region.</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Gastroenteritis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Sepsis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Malaria</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Haemorrhage</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Glomerulonephritis, especially in children</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Use of nephrotoxins – NSAIDs, aminoglycosides, ACEi / ARBs, diuretics overuse, metformin, herbal medications, contrast dyes</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Heart failure</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Liver failure</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Urinary tract obstruction - stones, tumours</p>
</div></li>
</ul>
<h2 id="risk-factors-for-aki">Risk factors for AKI </h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Patients older than 65 years of age</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>CKD</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Heart failure</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Liver disease</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Diabetes</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Haematological malignancy</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>History of AKI</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Neurological/cognitive impairment</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Reliance on carers for fluids</p>
</div></li>
</ul>
<h2 id="presenting-symptoms-and-signs">Presenting symptoms and signs</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Reduced urine volume or absent urine</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Features suggestive of uraemia including epigastric pain, haematemesis, haematochezia, chest pain, confusion, obtundation, loss of consciousness, increased somnolence, dyspnea, abnormal bleeding and bruising, generalised body weakness</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Features of the underlying causes: fever, vomiting, diarrhoea, haematuria</p>
</div></li>
</ul>
<h2 id="examination-findings">Examination findings</h2>
<p>This includes features of AKI (oliguria or anuria) as well as those of the underlying cause or complications.</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Oliguria or anuria</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Fever or hypothermia</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Pallor</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Dehydration</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Jaundice</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Oedema</p>
</div></li>
</ul>
<h2 id="investigations">Investigations</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Urinalysis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Urine microscopy</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Serum electrolytes, urea, creatinine, calcium and phosphate</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>FBC and blood film</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Renal ultrasound</p>
</div></li>
</ul>
<p><strong>Diagnosis of AKI</strong></p>
<p>The diagnosis of AKI is made if any <span class="underline">ONE</span> of the following criteria is fulfilled:</p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Increase in Cr by 26.5 µmol/l within 48 hours; or</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Increase in Cr ≥ 1.5 times baseline, which is known or presumed to have occurred within the prior 7 days; or</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Urine volume of ˂ 0.5 ml/kg/h for 6 hours (adults) or 8 hours (children); or</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>25% of greater fall in eGFR in children within past 7 days.</p>
</div></li>
</ul>
<p>The staging of AKI severity is determined by creatinine levels in adults and by creatinine clearance in children as well as urine output in both age groups</p>
<table>
<thead>
<tr class="header">
<th><strong>Stage</strong></th>
<th><strong>Children</strong></th>
<th><strong>Adults</strong></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td></td>
<td><strong>eGFR criteria</strong></td>
<td><strong>Urine output criteria</strong></td>
<td><strong>Creatinine criteria</strong></td>
<td><strong>Urine output criteria</strong></td>
</tr>
<tr class="even">
<td>1</td>
<td>eGFR decreased by 25%</td>
<td>&lt; 0.5ml/kg/hr x 8 hours</td>
<td><p>1.5 – 1.9 times base line Cr OR</p>
<p>Cr ≥ 26.5µmol from base line</p></td>
<td>&lt; 0.5 ml/kg/hr x 6 hours</td>
</tr>
<tr class="odd">
<td>2</td>
<td>eGFR decreased by 50%</td>
<td>&lt;0.5ml/kg/hr x16 hours</td>
<td>2.0-2.9 times baseline Cr</td>
<td>&lt;0.5 ml/kg/hr x12 hours</td>
</tr>
<tr class="even">
<td>3</td>
<td><p>eGFR decreased by 75% OR</p>
<p>eGFR &lt; 35 ml/min/1.73m<sup>2</sup></p></td>
<td>&lt;0.3 ml/kg/hr x 24 hours OR anuria (≤100ml) for 12 hours</td>
<td><p>≥ 3.0 times baseline Cr</p>
<p>OR</p>
<p>Cr ≥ 353.6µmol/L</p>
<p>OR</p>
<p>Initiation of renal replacement therapy</p></td>
<td>&lt;0.3 ml/kg/hr x 24 hours or anuria (≤100 ml) for 12 hours</td>
</tr>
</tbody>
</table>
<p>For children, the eGFR is calculated using the Bedside Schwartz formula which can be found on this link <a href="http://nephron.com/bedside_peds_nic.cgi"><span data-custom-style="Hyperlink">http://nephron.com/bedside_peds_nic.cgi</span></a>.</p>
<h2 id="management">Management </h2>
<p>Management of AKI is similar for both adults and children</p>
<h3 id="patients-at-risk">Patients at risk:</h3>
<p>Serum creatinine levels should be done at baseline and this should be repeated periodically. While on admission, creatinine levels should be done at least on a weekly basis (more often depending on the patient’s clinical status). Urine output should be monitored throughout admission.</p>
<h3 id="conservative-management">Conservative management: </h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Treat underlying cause e.g. antibiotics for sepsis, antimalarials for malaria etc.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Replace fluid losses (insensible water loss plus fluid loss from vomiting or diarrhea) with colloids, preferably containing saline.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Monitor input and output. Use urethral catheter only if it will be difficult to estimate urine volume or if a urethral obstruction is suspected.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Ensure patient is feeding well: High caloric intake with low to normal protein.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Manage electrolyte disturbances such as hyperkalaemia and metabolic acidosis using the guidelines on the management of electrolyte disturbances.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p><span class="underline">Note</span>: The use of diuretics is restricted to conditions in which there is fluid overload e.g. peripheral and pulmonary oedema. They should not be used routinely.</p>
</div></li>
</ul>
<h3 id="indications-for-renal-replacement-therapy-referral-to-efsth">Indications for renal replacement therapy (referral to EFSTH):</h3>
<p><strong>Biochemical</strong></p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Refractory hyperkalaemia of ≥ 6.5 mmol/L or 6 mmol/L with ECG changes or a daily rise of 1 mmol/L/ day</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Refractory metabolic acidosis : Bicarbonate levels ≤ 12 mmol/L</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Urea level of &gt; 25 mmol/L or increase of &gt;10 mmol/L/day</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Stage 3 AKI (Serum creatinine ≥ 353.6 µmol/L) or daily rise of ≥ 100 mmol/L/ day</p>
</div></li>
</ul>
<p><strong>Clinical</strong></p>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Refractory pulmonary oedema</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Uraemic gastritis with persistent symptoms</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Uraemic pericarditis</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Uraemic encephalopathy</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Bleeding diathesis</p>
</div></li>
</ul>
<h3 id="follow-up">Follow up:</h3>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Counsel patient on the prognosis of AKI and the need for follow up care.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Serum creatinine levels should be measured at least 90 days after recovery from AKI. Monitoring can be as frequent as monthly</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Follow up in clinic may be extended to the next 2-3 years to check for progression of the disease, even if creatinine levels are normal and stabilised.</p>
</div></li>
</ul>
<h2 id="key-issues-for-nursing-care">Key Issues for Nursing care</h2>
<ul>
<li><div data-custom-style="List Paragraph">
<p>Strict monitoring of patient’s input and output on the fluid balance chart with escalation of care where necessary.</p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Ensure adherence to the management protocol<strong>.</strong></p>
</div></li>
<li><div data-custom-style="List Paragraph">
<p>Restrict potassium-rich foods e.g. bananas, oranges, cooked spinach and potatoes.</p>
</div></li>
</ul>
<h2 id="references">References</h2>
<p>KDIGO A. K. I. Work Group (2012). KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl, 2(1), 1-138.</p>
<p>Soler, Y. A., Nieves-Plaza, M., Prieto, M., García-De Jesús, R., &amp; Suárez-Rivera, M. (2013). pRIFLE (Pediatric Risk, Injury, Failure, Loss, End Stage Renal Disease) score identifies Acute Kidney Injury and predicts mortality in critically ill children: a prospective study. Pediatric critical care medicine: a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies, 14(4), e189.</p>
<p><a href="https://www.nice.org.uk/guidance/cg169/evidence/acute-kidney-injury-full-guideline-pdf-191530621"><span data-custom-style="Hyperlink">https://www.nice.org.uk/guidance/cg169/evidence/acute-kidney-injury-full-guideline-pdf-191530621</span></a></p>
<p>Rahman, M., Shad, F., &amp; Smith, M. C. (2012). Acute kidney injury: a guide to diagnosis and management. American family physician, 86(7).</p>
<table>
<thead>
<tr class="header">
<th><strong>Written by:</strong></th>
<th>Orighomisan Agboghoroma</th>
<th>Date: 04 April 2019</th>
</tr>
</thead>
<tbody>
<tr class="odd">
<td><strong>Reviewed by:</strong></td>
<td>Karen Forrest</td>
<td>Date: 07 May 2019</td>
</tr>
<tr class="even">
<td><strong>Version:</strong></td>
<td><strong>Change history:</strong></td>
<td><strong>Review due date:</strong></td>
</tr>
<tr class="odd">
<td>1.0</td>
<td>New document</td>
<td>31 May 2021</td>
</tr>
<tr class="even">
<td>Review Comments (<em>if applicable)</em></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
</article>
</body>
</html>
